CN115212196A - New application of aeginetia indica polyene compounds - Google Patents

New application of aeginetia indica polyene compounds Download PDF

Info

Publication number
CN115212196A
CN115212196A CN202210987194.3A CN202210987194A CN115212196A CN 115212196 A CN115212196 A CN 115212196A CN 202210987194 A CN202210987194 A CN 202210987194A CN 115212196 A CN115212196 A CN 115212196A
Authority
CN
China
Prior art keywords
polyene
aeginetia
indica
aeginetia indica
polyene compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210987194.3A
Other languages
Chinese (zh)
Other versions
CN115212196B (en
Inventor
阮丽君
宋志军
姚彩云
缪剑华
吴云秋
杨晓男
闫炳雄
刘喜慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangxi Botanical Garden of Medicinal Plants
Original Assignee
Guangxi Botanical Garden of Medicinal Plants
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangxi Botanical Garden of Medicinal Plants filed Critical Guangxi Botanical Garden of Medicinal Plants
Priority to CN202210987194.3A priority Critical patent/CN115212196B/en
Publication of CN115212196A publication Critical patent/CN115212196A/en
Application granted granted Critical
Publication of CN115212196B publication Critical patent/CN115212196B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention discloses a new application of aeginetia indica polyene compounds, which is to use aeginetia indica polyene compounds as active ingredients to prepare drugs or health-care foods for preventing or treating liver diseases. The experimental results show that: aeginetia multiolefin E and scrophularia erythronic acid can improve the survival rate of the APAP-induced HepG2 cells, and show certain protective activity on liver cells; aeginetia indica polyene E and figwort red acid can effectively reduce CCl 4 The SOD activity of rat liver tissue can be obviously improved, and the SOD has certain prevention and treatment effects on liver injury. Therefore, the aeginetia indica polyene compounds are used as active ingredients for preparing the drugs or health care products for preventing and treating liver diseasesThe application of the aeginetia indica polyene compounds has important significance for the research and the application of the aeginetia indica polyene compounds.

Description

New application of aeginetia indica polyene compounds
Technical Field
The invention belongs to a new application of aeginetia indica polyene compounds, and particularly relates to a new application of aeginetia indica polyene compounds in preparation of drugs for preventing or treating liver diseases.
Background
The liver is the central organ of human metabolism and nutrition, not only completes the synthesis and decomposition of carbohydrates, proteins and fats, but also needs the transformation of most endogenous and exogenous metabolic end products through the liver. Liver diseases are one of common diseases in modern life, when liver functions are in problem, digestive functions can be directly influenced, the digestion function is reduced, appetite is easily caused, absorption is influenced, sufficient energy cannot be provided for human bodies if digestion and absorption are carried out for a long time, and then the problems that the human bodies are easily fatigued, cannot concentrate, are dizziness and tinnitus can be caused, and even people can be in a worry.
Liver diseases, i.e., liver injury, include mainly viral hepatitis, alcoholic hepatitis and drug-induced hepatitis, which are clinically manifested as hepatic necrosis, fatty liver, cholestasis, hepatic fibrosis, cirrhosis, liver cancer, and the like, and the treatment of liver injury is still a global serious topic at present. Carbon tetrachloride is a hepatic fibrosis inducer and is often used in experiments of acute hepatic injury, namely, a mouse hepatic injury model is obtained by injecting carbon tetrachloride, and the hepatic injury condition is judged by detecting the contents of alanine aminotransferase (ALT/GPT), aspartate aminotransferase (AST/GOT) and superoxide dismutase (SOD) and propylene glycol (MDA) in liver tissues in the serum of a mouse.
Aeginetia polyene compounds, including Aeginetin (Aeginetin), azafrin (Azafrin), extracted from Orobanchaceae (Orobanchaceae), aeginetia (Aeginetia), carotenoid type, are commonly used for treating sore throat, cough, infantile hyperpyrexia, urinary tract infection, osteomyelitis and venomous snake bite.
However, no research report on the aeginetocin compound in preventing or treating liver diseases is found so far.
Disclosure of Invention
The object of the present invention is to solve at least the above drawbacks and to provide advantages which will be explained later.
In order to achieve these objects and other advantages of the present invention, a new use of aeginetobacter asiaticum polyene compounds is now provided, wherein aeginetobacter asiaticum polyene compounds are used as active ingredients for preparing drugs or health foods for preventing or treating liver diseases.
In the scheme, particularly, when the aeginetolide is used as an active ingredient for preparing a medicament or a health-care food for preventing or treating liver diseases, the aeginetolide can be prepared into oral medicaments or non-oral medicaments; wherein, the oral administration can be made into any conventional dosage forms, such as tablet, capsule, powder, granule, etc.; it can be made into injection for non-oral administration. Therefore, the method is suitable for various application scenes and has good market prospect.
Preferably, the aeginetoides polyene compound has the following chemical structural formula, which is referred to as chemical formula I for short:
Figure BDA0003802288110000021
wherein n is greater than or equal to 1.
Preferably, the compound is aeginetocin E, and has the following chemical structural formula, which is simply called chemical formula II:
Figure BDA0003802288110000022
preferably, the compound is scrophularia erythronic acid, and has the following chemical structural formula, which is referred to as chemical formula III for short:
Figure BDA0003802288110000023
the preparation method of the aeginetoides polyene compounds is characterized by comprising the following steps:
step one, wild rice is obtained and crushed to obtain wild rice powder.
And step two, repeatedly leaching the wild rice powder for 3 times by using an ethanol solution with the volume fraction of 70-80%, and combining the liquid obtained by leaching for 3 times to obtain a leaching solution.
And step three, sequentially filtering and concentrating the obtained leaching liquor under reduced pressure to obtain a crude extract.
And step four, dissolving the crude extract with water to obtain a crude extract, and sequentially performing petroleum ether extraction and ethyl acetate extraction to obtain the aeginetia indica ethyl acetate extract.
And step five, dissolving the aeginetia indica ethyl acetate extract by using methanol, filtering, separating by using an MCI column, concentrating a 60% methanol eluent, and separating out yellow solid to obtain the aeginetia indica polyene compound.
The feed-liquid ratio of the aeginetosa powder to the ethanol solution is 1:10 to 30 parts; the volume ratio of the ethyl acetate to the crude extract is 0.5-2: 1.
the preparation method of the aeginetoides polyene compounds is characterized by comprising the following steps:
step one, aeginetia indica is obtained and crushed to obtain aeginetia indica powder.
And step two, repeatedly leaching the wild rice powder for 3 times by using an ethanol solution with the volume fraction of 70-80%, and combining the liquid obtained by leaching for 3 times to obtain a leaching solution.
And step three, sequentially filtering and concentrating the obtained leaching liquor under reduced pressure to obtain a crude extract.
And step four, dissolving the crude extract with water to obtain a crude extract, and sequentially performing petroleum ether extraction and ethyl acetate extraction to obtain the aeginetia indica ethyl acetate extract.
And step five, dissolving the aeginetia indica ethyl acetate extract by using methanol, filtering, separating by using an MCI column, concentrating 85% methanol eluent, and separating out red solid to obtain aeginetia indica polyene compound and figwort red acid.
Preferably, the MCI column is an 8 × 20 cm small-hole resin column; the MCI column separation specifically comprises: passing through a column by adopting a methanol-water ratio; the gradient elution was set to a ratio of pure water to methanol of 100: 0. 80: 20. 60: 40. 40: 60. 15: 85. 0:100, 1L per ratio.
Preferably, the medicine is a medicinal preparation prepared by taking the aeginetoides polyene compound as an active ingredient and adding pharmaceutically acceptable carriers or auxiliary ingredients.
The invention has the advantages that:
firstly, the invention can promote the aeginetia indica polyene compound to fully exert the medicinal value thereof, and has important significance for the research and application of the aeginetia indica polyene compound.
Secondly, the aeginetia polyene E and the scrophularia erythronic acid are extracted from aeginetia plants to prepare the medicine for preventing and treating the liver diseases, so that the pain and trouble caused by surgical excision, chemotherapy, radiotherapy and the like can be reduced.
In addition, when the aeginetoides polyene compound is used as an active ingredient for preparing a medicament or health-care food for preventing or treating liver diseases, the aeginetoides polyene compound can be prepared into oral medicaments or non-oral medicaments; wherein, the oral administration medicine can be made into any conventional dosage forms, such as tablets, capsules, powder, granules and the like; it can be made into injection for non-oral administration. Therefore, the method is suitable for various application scenes and has good market prospect.
Detailed Description
The present invention is further described in detail below with reference to examples to enable those skilled in the art to practice the invention with the help of the following description.
It will be understood that terms such as "having," "including," and "comprising," as used herein, do not preclude the presence or addition of one or more other elements or groups thereof.
It is to be noted that the experimental methods described in the following embodiments are all conventional methods unless otherwise specified, and the reagents and materials are commercially available unless otherwise specified.
Example 1
1 extraction and separation of aeginetia indica polyene compounds
Step one, drying 20kg of aeginetia indica whole grass, and crushing to obtain aeginetia indica powder.
Dispersing wild mushroom powder into an ethanol solution with the volume fraction of 70-80%, soaking for 5 days at normal temperature, extracting, repeatedly soaking and extracting for 3 times, and combining the liquid obtained by 3 times of leaching to obtain a leaching solution; wherein the feed-liquid ratio of the aeginetia indica powder to the ethanol solution is 1:10 to 30.
And step three, sequentially filtering and concentrating the leaching liquor obtained in the step two under reduced pressure to obtain a crude extract.
Step four, dissolving the crude extract with water to obtain a crude extract, extracting with petroleum ether to remove fat-soluble impurities, and then extracting the crude extract with ethyl acetate to obtain a aeginetia indica ethyl acetate extract; wherein the volume ratio of the ethyl acetate to the crude extract is 0.5-2: 1.
step five, dissolving the aeginetia indica ethyl acetate extract by using methanol, filtering, separating by using a small-hole resin column (MCI filler) with the size of 8 multiplied by 20 cm, concentrating a 60% methanol eluent, and separating out yellow solid which is aeginetia indica polyene E and accounts for 6.8 g; concentrating 85% methanol eluate to obtain 0.6 g red solid of radix scrophulariae erythronic acid; wherein the weight ratio of the ethyl acetate extract to the MCI filler is 1:40 to 50; the elution process adopts water-methanol gradient elution, and the gradient elution is set as the ratio of pure water to methanol is respectively 100: 0. 80: 20. 60: 40. 40: 60. 15: 85. 0:100, 1L per ratio.
2 structural identification of aeginetia indica polyene compounds
2.1 Structure of aeginetia polyene compounds:
Figure BDA0003802288110000041
2.2 nuclear magnetic resonance data (Varian-600 MHz NMR) of aeginetopsis polyacea:
1 H NMR(600MHz，d-CD 3 OD):δ H 7.33(d，J＝11.8Hz，1H)，7.05–6.94(m，1H)，6.81(dd，J＝15.0，11.5Hz，1H)，6.67–6.57(m，1H)，6.43(d，J＝9.8Hz，1H)，6.40(d，J＝8.9Hz，1H)，6.32(d，J＝12.6Hz，1H)，6.30(d，J＝16.2Hz，1H)，6.21(d，J＝11.3Hz，1H)，2.03(s，3H)，2.00(s，3H)，1.95(s，3H)，1.91–1.86(m，1H)，1.85–1.78(m，1H)，1.71(td，J＝13.1，3.2Hz，1H)，1.47(d，J＝12.4Hz，1H)，1.40–1.33(m，1H)，1.21(s，3H)，1.17(d，J＝13.5Hz，1H)，1.09(s，3H)，0.81(s，3H).
13 C-NMR(151MHz，d-CD 3 OD):δ C 171.96，141.20，140.38，137.92，137.73，137.27，135.52，132.52，132.35，131.80，129.17，127.91，127.35，80.71，76.02，39.68，37.47，36.76，27.55，27.37，25.75，19.09，13.26，12.95，12.83。
2.3 nuclear magnetic resonance data of the compound scrophularia erythronic acid:
1 H NMR(600MHz，d-CD 3 OD):δ H 7.38(d，J＝15.5Hz，1H)，6.96–6.87(m，1H)，6.78(dd，J＝15.0，11.5Hz，1H)，6.75–6.66(m，1H)，6.60(d，J＝11.7Hz，1H)，6.42(dd，J＝15.5，10.5Hz，2H)，6.32(d，J＝11.9Hz，2H)，6.29(d，J＝16.0Hz，1H)，6.21(d，J＝11.4Hz，1H)，5.87(d，J＝15.5Hz，1H)，2.02(s，3H)，2.00(s，3H)，1.95(s，3H)，1.92–1.88(m，1H)，1.83(d，J＝3.7Hz，1H)，1.71(td，J＝13.1，3.3Hz，1H)，1.47(d，J＝13.1Hz，2H)，1.40–1.35(m，2H)，1.29(s，2H)，1.21(s，3H)，1.17(d，J＝13.1Hz，1H)，1.09(s，3H)，0.81(s，3H).
13 C-NMR(151MHz，d-CD 3 OD):δ C 170.97，159.59，150.61，140.84，140.18，138.10，137.44，135.56，135.40，134.48，132.93，132.34，131.93，129.98，127.47，117.19，80.71，76.02，39.68，37.46，36.76，27.56，27.38，25.75，19.09，13.26，12.92，12.56。
3 activity test of aeginetia indica polyene compounds
3.1 protective Activity of Aeginetia indica polyene Compounds on APAP-induced HepG2 cells
(1) Test method
Step a, taking people in logarithmic growth phaseHepatoma cell line HepG2, and preparing a single cell suspension of the HepG2 cell culture solution with the RPMI-1640 culture solution containing 10% fetal bovine serum, inoculating the suspension into a 96-well plate in an amount of 2000 cells per well, in a volume of 100. Mu.l per well, in 5% CO 2 The culture was carried out at a concentration of 37 ℃ for 24 hours in an incubator.
B, the medicine components are aeginetia polyene E group and figwort red acid group, and the aeginetia polyene E or the figwort red acid and acetaminophen (APAP, 8 mM) are used for treating cells together respectively; the positive control group treated cells with APAP and Bicyclol (Bicyclol) together; model groups treated cells with acetaminophen; blank groups were left untreated. The above fractions were treated and incubated for 24 hours.
And c, after the incubation is finished, adding 5mg/ml MTT solution into each hole, continuously culturing for 4 hours, sucking the culture solution, adding DMSO, shaking uniformly, then incubating for 3 hours, finally measuring the OD value at 517nm on an enzyme-linked immunosorbent monitor, and calculating the cell survival rate (%).
(2) Calculation of cell viability
Cell viability% = experimental group OD value/blank group OD × 100%. The results are shown in Table 2.
Table 1: aeginetoxico polyene E and scrophularia erythronic acid have protective activity on HepG2 liver cells (n =5, ** P＜0.01)
Figure BDA0003802288110000061
(3) Analysis of results
Compared with a model group, the aeginetia polyene E and the scrophularia erythronic acid can improve the survival rate of the APAP-induced HepG2 cells and show certain protective activity on liver cells.
3.2 Aeginetia polyakenes on CCl 4 Protective action for rat liver damage
(1) Inspection method
Solution preparation: weighing wild mushroom polyene E and radix scrophulariae erythronic acid, and dissolving with 0.5% CMC-Na to obtain 100mg/mL concentration.
Animal administration: 40 male rats were randomly divided into a blank group and a model groupAeginetia indica polyene E and figwort red acid groups, wherein each group comprises 10 aeginetia indica polyene E and figwort red acid groups. Gavage polyene E and radix scrophulariae erythrocid group are administered according to 100mg/Kg intragastric administration, and the normal control group and model group are both administered with equal amount of 0.5% CMC-Na solution, and are intragastric administered for 1 time per day, and are continuously administered for 7 days. After 2h of the last administration, except the blank group, the mice of the other groups were injected with 0.2% carbon tetrachloride (CCl) intraperitoneally 4 ) 20mL/Kg of olive oil solution. After fasting without water deprivation for 16h, weighing was performed, mice were killed by dislocation, and blood samples and liver tissues were collected for further examination.
And (3) detection: serum is detected by a kit, and glutamic-pyruvic transaminase (ALT) and glutamic-oxalacetic transaminase (AST) in the serum are determined according to the instruction. Liver tissue was weighed to 200mg, homogenized in 1.8mL of pre-cooled physiological saline, centrifuged at 1500 Xg for 5min, and the homogenate collected. The homogenate was first assayed for protein concentration in the homogenate according to the Bio-Rad protein assay kit method. Then, taking the homogenate, and detecting the SOD activity, MDA content and ROS generation level of the homogenate according to the steps of the detection kit specification. Finally, the contents of the above factors in the homogenate are normalized according to the protein concentration.
(2) Test results
The test results are expressed as means + -standard deviation (mean + -SD), and pairwise comparison of means between sets of data was performed using a one-way ANOVA post-hoc SNK-q test. Differences were considered statistically significant when P < 0.05. The results are shown in Table 2.
Table 2: influence of aeginetocin E and scrophularia erythronolic acid on rat serum index (n = 8)
Figure BDA0003802288110000071
(3) Analysis of results
Compared with the control group, the wild mushroom polyene E group has significantly increased ALT and AST activities (P) in the rat serum of the model group<0.01). Compared with the model group, the ALT and AST activities in the rat serum of aeginetia indica polyene E group and figwort red acid group are both reduced (P)<0.01 And the aeginetia indica polyene E group and the scrophularia erythropolis acid group have no obvious difference. These results indicate that aeginetia polyene E and scrophularia erythronic acid can both alleviate CCl 4 Leading to severe liver diseaseLiver damage in mice.
The antioxidant enzyme SOD activity in rat liver tissue of the model group is obviously reduced (P)<0.01 ); compared with the model group, the SOD activity in the liver tissues of the rats of the aeginetia indica polyene E group and the figwort red acid group is obviously increased (P)<0.01 And the scrophularia rubra group is more remarkable than the aeginetia indica polyene E group. Compared with the blank group, the liver tissue of the rat in the model group has obviously increased MDA content (P)<0.01 Reflecting the rise of lipid peroxidation degree in the rat body; compared with the model group, the rat liver tissues of the aeginetia indica polyene E group and the figwort red acid group have obviously reduced MDA content (P)<0.01). Measurement of ROS levels in rat liver showed that the ROS production levels in the liver tissue of the model group rats were increased compared to the blank group (P)<0.01 ); the levels of ROS production were significantly reduced in the liver tissues of rats in the aeginetia polyene E group and the scrophularia erythronic acid group (P) compared to the model group (P)<0.01 The effect is particularly obvious in a high-dose group (P)<0.01). The results show that aeginetia indica polyene E and scrophularia erythronic acid can reduce CCl 4 Resulting in oxidative stress levels in liver tissues of rats with liver diseases.
While embodiments of the invention have been disclosed above, it is not intended that they be limited to the applications set forth in the specification and examples. It can be applied to all kinds of fields suitable for the present invention. Additional modifications will readily occur to those skilled in the art. The invention is therefore not to be limited to the specific details described herein, without departing from the general concept as defined by the appended claims and their equivalents.

Claims (8)

1. A new application of aeginetoides polyene compounds is characterized in that aeginetoides polyene compounds are used as active ingredients for preparing medicines or health-care foods for preventing or treating liver diseases.
2. The new use of aeginetia indica polyene compound of claim 1, wherein the aeginetia indica polyene compound has the following chemical structural formula, chemical formula i for short:
Figure FDA0003802288100000011
wherein n is greater than or equal to 1.
3. The new use of aeginetobacter asiaticum polyene compounds according to claim 2, wherein said aeginetobacter asiaticum polyene compounds is aeginetobacter asiaticum polyene E, having the following chemical structural formula, abbreviated as chemical formula ii:
Figure FDA0003802288100000012
4. the new use of aeginetia polyene compound according to claim 2, wherein the aeginetia polyene compound is scrophularia erythronic acid, and has the following chemical structural formula, chemical formula iii for short:
Figure FDA0003802288100000013
5. the preparation method of the aeginetoides polyene compounds is characterized by comprising the following steps:
step one, obtaining wild rice and crushing to obtain wild rice powder;
step two, repeatedly leaching the wild rice powder for 3 times by using an ethanol solution with the volume fraction of 70-80%, and combining the liquid obtained by leaching for 3 times to obtain a leaching solution;
step three, sequentially filtering and concentrating the obtained leaching liquor under reduced pressure to obtain a crude extract;
step four, dissolving the crude extract with water to obtain a crude extract, and sequentially performing petroleum ether extraction and ethyl acetate extraction to obtain a aeginetia indica ethyl acetate extract;
step five, dissolving aeginetia indica ethyl acetate extract by using methanol, filtering, separating by using an MCI column, concentrating 60% methanol eluent, and separating out yellow solid to obtain aeginetia indica polyene compound of claim 2;
the feed-liquid ratio of the wild mushroom powder to the ethanol solution is 1:10 to 30 percent; the volume ratio of the ethyl acetate to the crude extract is 0.5-2: 1.
6. the method for preparing aeginetopes compounds according to claim 5, wherein the fifth step is:
step five, dissolving aeginetia indica ethyl acetate extract by using methanol, filtering, separating by using an MCI column, concentrating 85% methanol eluent, and separating out red solid to obtain aeginsenolic acid of the aeginetia indica polyene compound in claim 3.
7. The preparation method of aeginetoides polyene compounds according to any one of claims 5 or 6, wherein the MCI column is a small-hole resin column of 8 x 20 cm; the MCI column separation specifically comprises:
passing through a column by adopting a methanol-water ratio; the gradient elution was set to a ratio of pure water to methanol of 100: 0. 80: 20. 60: 40. 40: 60. 15: 85. 0:100, 1L per ratio.
8. The new use of aeginetia indica polyene compound according to any one of claims 1 to 4, wherein the medicament is a pharmaceutical preparation prepared by using aeginetia indica polyene compound as an active ingredient and adding pharmaceutically acceptable carriers or auxiliary ingredients.
CN202210987194.3A 2022-08-17 2022-08-17 Application of aeginetia mulosa polyene compound Active CN115212196B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210987194.3A CN115212196B (en) 2022-08-17 2022-08-17 Application of aeginetia mulosa polyene compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210987194.3A CN115212196B (en) 2022-08-17 2022-08-17 Application of aeginetia mulosa polyene compound

Publications (2)

Publication Number Publication Date
CN115212196A true CN115212196A (en) 2022-10-21
CN115212196B CN115212196B (en) 2023-09-29

Family

ID=83615663

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210987194.3A Active CN115212196B (en) 2022-08-17 2022-08-17 Application of aeginetia mulosa polyene compound

Country Status (1)

Country Link
CN (1) CN115212196B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258158A (en) * 1994-03-14 1995-10-09 Marigen Sa Biotenside solvent for medicine and cosmetic
CN102772397A (en) * 2012-08-06 2012-11-14 上海中医药大学 New application of azafrin
CN103254163A (en) * 2013-05-17 2013-08-21 南京泽朗医药科技有限公司 Preparation method of aeginetolide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258158A (en) * 1994-03-14 1995-10-09 Marigen Sa Biotenside solvent for medicine and cosmetic
CN102772397A (en) * 2012-08-06 2012-11-14 上海中医药大学 New application of azafrin
CN103254163A (en) * 2013-05-17 2013-08-21 南京泽朗医药科技有限公司 Preparation method of aeginetolide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHUYU YANG , ET AL: ""Cardioprotective role of azafrin in against myocardial injury in rats via activation of the Nrf2-ARE pathway"", 《PHYTOMEDICINE》, vol. 18, pages 1 - 22 *

Also Published As

Publication number Publication date
CN115212196B (en) 2023-09-29

Similar Documents

Publication Publication Date Title
CN106336445B (en) The preparation method and application of compound 20 (R) ginseng sapoglycoside Rg 3
CN104644697B (en) The preparation method and applications of ganoderma lucidum Ultramicro-powder
CN111166734A (en) Use of naphthoquinones to treat pneumonia caused by pathogenic organisms
CN106822166B (en) A kind of drug for preventing and treating diabetes and hyperlipidemia and its application in pharmacy
CN104688760A (en) Pharmaceutical composition composed of saikoside A and taurine and use thereof
CN112353792A (en) Application of eupatilin in preparing medicament for preventing or treating alcoholic liver disease
CN103360452B (en) The Synthesis and applications of Muskmelon Base tetracyclic triterpene cucurbitane compound
CN115212196A (en) New application of aeginetia indica polyene compounds
WO2021120966A1 (en) Sheep horn keratin, preparation method therefor, pharmaceutical composition thereof and use thereof
CN103494813A (en) Application of hydrochloric acid demethyleneberberine in preparation of drug for preventing and/or treating acute or chronic alcoholic liver disease
CN106995479A (en) Compound ginsenoside Rk1 preparation method and application
CN113797235A (en) Preparation method of compound ganoderma lucidum spore oil with liver protection effect
CN103830374A (en) Application of three-leaf glycolipid-removal medicine in hyperuricemia
CN104367612B (en) A kind of application of dog ant grass extract
TWI620815B (en) Preparation and use of antrodia cinnamomea mycelia fermentation product for improving nonalcoholic steatohepatitis (nash)
CN108186693B (en) Preparation method of paecilomyces hepiali active substance for reducing uric acid or treating hyperuricemia, active substance prepared by method and application thereof
CN102342962A (en) Application of extracts from Portulaca oleracea L. in preparation of anti-liver injury medicines and health foods
CN111329871A (en) Preparation method and application of product of cordyceps militaris for preventing and treating liver cancer
WO2018188547A1 (en) New use of cordyceps sobolifera
CN110840950A (en) Application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver disease and/or non-alcoholic liver injury
WO2018188548A1 (en) Traditional chinese medicine composition with hypoglycemic effect
CN114272354B (en) Traditional Chinese medicine composition for preventing and improving senile dementia, preparation method and application thereof
CN107595934A (en) A kind of walnut grouts polyphenol purified is preparing the purposes in treating intestinal bacilli illness medicine
CN104069149A (en) Method for processing traditional Chinese medicine decoction piece by using bear gall as matrix
CN102793740B (en) Nutrient particles with auxiliary protecting function on chemical liver injury

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20221021

Assignee: GUANGXI HENGDERUN BIOLOGICAL SCIENCE & TECHNOLOGY Co.,Ltd.

Assignor: GUANGXI BOTANICAL GARDEN OF MEDICINAL PLANTS

Contract record no.: X2023980045685

Denomination of invention: The Use of Wild Rice Polyene Compounds

Granted publication date: 20230929

License type: Common License

Record date: 20231106